RESUMO
Most adolescents are cared for by general pediatricians, family practitioners, and mid-level providers. As a result, primary care practitioners need to be prepared to answer questions from adolescent patients and their parents about sexually transmitted infections (STIs), to practice good preventive medicine through screening and vaccination, and to provide treatment of STIs when needed. Although the topic of STIs is broad, there are common scenarios that arise in adolescent care. This review takes a pragmatic look at some of the most routine topics in adolescent health care regarding STIs, including the provision of confidential care, discussions with adolescent patients and their parents about human papillomavirus vaccination, the diagnosis and treatment of urethritis and cervicitis, and STI screening recommendations. [Pediatr Ann. 2019;48(9):e370-e375.].
Assuntos
Atenção Primária à Saúde/métodos , Infecções Sexualmente Transmissíveis/diagnóstico , Infecções Sexualmente Transmissíveis/terapia , Adolescente , Confidencialidade/ética , Confidencialidade/psicologia , Medicina de Família e Comunidade , Medicina Geral , Humanos , Vacinas contra Papillomavirus , Pediatria , Relações Médico-Paciente , Serviços Preventivos de Saúde/métodos , Relações Profissional-Família , Infecções Sexualmente Transmissíveis/psicologiaRESUMO
BACKGROUND & AIMS: Emphasis on adolescent HIV has increased worldwide as antiretroviral treatment has greatly extended life expectancies of HIV-positive children. Few evidence-based guidelines exist on the optimal time to disclose to an adolescent living with HIV (ALHIV); little is known about the medical effects of disclosure. This study looked to determine whether disclosure is associated with improved medical outcomes in ALHIV. Prior work has tended to be qualitative, cross-sectional, and with an emphasis on psychosocial outcomes. This paper addresses the adolescent cohort retrospectively (longitudinally), building upon what is already known about disclosure. METHODS: Retrospective, longitudinal clinical record reviews of ALHIV seen at Kericho District Hospital between April 2004 and November 2012 were performed. Patient demographics and clinical outcomes were systematically extracted. The student's t-test was used to calculate changes in mean CD4 count, antiretroviral therapy (ART), and cotrimoxazole adherence pre- vs. post-disclosure. Linear regression modelling assessed for trends in those clinical outcomes associated with age of disclosure. RESULTS: Ninety-six ALHIV (54 female, 42 male) were included; most (73%) entered care through the outpatient department. Nearly half were cared for by parents, and 20% experienced a change in their primary caregiver. The mean time in the study was 2.47 years; mean number of visits 10.97 per patient over the mean time in the study. Mean disclosure age was 12.34 years. An increase in mean ART adherence percentage was found with disclosure (0.802 vs. 0.917; p = 0.0015). Younger disclosure age was associated with significantly higher mean CD4 counts over the course of the study (p = 0.001), and a nonsignificant trend toward a higher mean ART adherence percentage (p = 0.055). CONCLUSION: ART adherence and improved immunologic status are both associated with disclosure of HIV infection to adolescent patients. Disclosure of an HIV diagnosis to an adolescent is an important means to improve HIV care.